Merck

Owkin Partners Merck to Develop & Commercialise AI-Powered Diagnostics December 22, 2023 This partnership seeks to develop a pre-screening procedure to improve testing rates for MSI-H in four types of cancer - endometrial, gastric, small intestinal, and biliary. In these cancer types, MSI-H prevalence is low and MSI-H screening is not routinely performed.

Merck to Acquire Caraway Therapeutics for Close to $610 Mn in a Push for Neurodegenerative Disease Therapies November 23, 2023 The agreement includes earnout milestones linked to the development of specific pipeline candidates. Through its MRL Ventures Fund, Merck has been a shareholder in Caraway Therapeutics since 2018.

Merck Launches ChemisTwin, First Ever Digital Reference Materials Platform for Analytical Testing November 17, 2023 ChemisTwin, the automation and calibration tool is easy to use and intuitive. This initiative seeks to contribute to advancing scientific research, product development, quality control, and regulatory compliance.

Merck Invests $100 Million in AMR Fund, Collaborates with Over 20 Companies October 6, 2023 American pharmaceutical giant, Merck, has entered into a partnership with over 20 pharmaceutical companies and organisations, committing to invest $100 million in the Antimicrobial Resistance (AMR) Action Fund over the next 10 years.

Germany-Based Merck Enters Two Strategic Collaborations to Strengthen AI-Driven Drug Discovery September 22, 2023 Germanys prominent science and technology player, Merck has entered into two strategic drug discovery collaborations with BenevolentAI, London, UK, and Exscientia, Oxford, UK.